Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04475510 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke

Study acronym: HALTI
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 24, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 1, 2025 to Jun 1, 2026v6
  2. Primary completion date: Jun 1, 2024 to Jun 1, 2025v5
  3. Primary completion date: Aug 1, 2022 to Jun 1, 2024v4
  4. Primary completion date: Aug 1, 2021 to Aug 1, 2022v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Start date changed from estimate of Aug 1, 2020 to Jul 8, 2020
    • Secondary endpoints revised (20)
    • Site details revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Josep Rodes-Cabau
4 trials monitored
See all monitored trials
Heart Disease
8,786 trials monitored
See 412 trials at risk
Stroke
3,531 trials monitored
See 153 trials at risk
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Trial Details
NCT Number NCT04475510
Lead Sponsor Josep Rodes-Cabau
Conditions
(from sponsor)		 Patent Foramen Ovale, Ischemic Stroke, Bleeding Ulcer
Related terms Foramen Ovale, Patent, Hemorrhage, Ischemic Stroke
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov